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ABSTRACT
Background: Data are limited on the effectiveness of anti-TNF and other biologics on psoriatric arthritis
(PsA) in Central and Eastern Europe (CEE). The objective of this analysis was to evaluate the efficacy of
etanercept (ETN) in PsA patients from CEE.
Methods: In PRESTA, patients were randomized to receive ETN 50mg BIW or 50mg QW for 12 weeks
(double-blind phase) and ETN 50mg QW for 12 additional weeks (open label). In this analysis, only
patients from Czech Republic, Hungary, Poland and Serbia were included. The primary efficacy variable
was the proportion of subjects achieving a physician global assessment (PGA) of psoriasis status: “clear” or
“almost clear” at week 12.
Results: In the 307 patients, 54% BIW/QW compared with 40% (QW/QW) (p¼ .02), achieved “clear”/
”almost clear” for PGA of psoriasis at week 12 increasing, to 68% and 60%, respectively (p¼ .134) by week
24. Mean improvement from baseline in PASI were 59% versus 49% (p¼ .005) at week 6 and 87% versus
81% (p< .05) at week 24, for the BIW/QW and QW/QW groups, respectively. ETN was well tolerated in
both groups over 24weeks.
Conclusions: Both dose regimens of ETN provided significant improvements in efficacy in PsA treatment
and were well tolerated.
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Introduction
Psoriatic arthritis (PsA) is a chronic, progressive, inflammatory
arthropathy affecting up to 40% of patients with skin or nail psor-
iasis (1). If not treated adequately, joint disease in PsA can lead to
irreversible bone damage resulting in compromised physical func-
tion and a reduced quality of life.
The need to treat two diseases simultaneously can make the
comanagement of PsA and psoriasis challenging. The presence of
elevated tumor necrosis factor (TNF) levels in both psoriatic skin
lesions and synovial fluid from joints affected by PsA has led to
the use of anti-TNF biologics to treat both skin and joint manifes-
tations (2–5). Although the effectiveness of anti-TNF agents and
other biologics is well established through clinical trials in the
USA and Western Europe, there are relatively few data related to
other parts of the world, such as Central and Eastern Europe
(CEE).
In the PRESTA (Psoriasis Randomized Etanercept Study in
Subjects with Psoriatic Arthritis) study, two dose regimens of eta-
nercept (ETN) were evaluated (ETN 50mg twice weekly [BIW] for
12weeks followed by ETN 50mg once weekly [QW] or ETN 50mg
QW for 24weeks) (6). Both dose groups showed significant
improvements in skin and joint symptoms and quality of life
measures with no new safety signals. PRESTA was a multinational
trial that included patients from countries in CEE. The objective of
this subset analysis is to evaluate the efficacy of ETN therapy in
patients from these countries compared with the overall study
population.
Methods
Study group
The details of the PRESTA trial (Clinicaltrials.gov Identifier:
NCT00245960) have been previously published (6). PRESTA was a
randomized, 24-week, multicenter study enrolling adult
(18 years of age) patients diagnosed with active but stable pla-
que psoriasis involving at least 10% of body surface area and a
physician’s global assessment (PGA) of psoriasis of moderate-to-
severe at baseline. In addition, all patients had active PsA defined
as 2 swollen joints, 2 tender joints, joint pain for 3 months
and a negative serum rheumatoid factor within 6months prior to
screening. Patients were randomized to receive ETN 50mg BIW
or 50mg QW for 12 weeks in a double-blind phase and open-
label ETN 50mg QW for 12 additional weeks. For this post hoc
analysis, only patients who participated in PRESTA from four CEE
countries (Czech Republic, Hungary, Poland and Serbia) were
included.
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Efficacy and safety assessments
The primary efficacy variable was the proportion of subjects who
achieved a PGA of “clear” or “almost clear” at week 12. This
assessment was reported on a scale ranging from 0 to 5, with 0
indicating no psoriasis (clear skin), 1 being almost clear and 5 indi-
cating severe disease.
Secondary endpoints reported in this subset analysis included
the PGA status at week 24; mean percentage improvements from
baseline in PGA; psoriasis area and severity index (PASI); PGA for
arthritis, painful and swollen joints; enthesitis and dactylitis at
weeks 12 and 24; proportion of patients who achieved PASI 50/
75/90 response; American College of Rheumatology (ACR) 20/50/
70 response and Psoriatic Arthritis Response Criteria (PsARC)
response at weeks 12 and 24, as well as the change in C-reactive
protein (CRP) levels. Safety assessments included physical exami-
nations, laboratory analyses and reporting of adverse events (AEs)
that was collected by telephone up to two weeks after the study.
Statistical analysis
Detailed information on the statistical analyses in the PRESTA
study has been described previously (7). Efficacy and safety analy-
ses were conducted on the modified intention to treat (mITT)
population, which included all randomized subjects receiving 1
dose of test drug and who had at least one postbaseline efficacy
evaluation. Endpoint measurements that were based on the pro-
portions of subjects were compared using the Mantel–Haenszel v2
test. Analysis of covariance (ANCOVA) models using baseline value
as covariant were used for continuous and ordinal endpoints.
(ANOVA was used when the baseline value was not available.)
Mean percent change was calculated from the change mean div-
ided by baseline mean. Efficacy analyses used the last-observa-
tion-carried-forward approach for missing data imputation.
Statistical testing was done at a¼ .05 level, two-sided testing,
without any adjustment for multiple comparisons unless otherwise
specified.
Results
Baseline demographics
Of the 752 patients randomized to either the ETN 50mg BIW/QW
or the ETN 50mg QW/QW arm in the PRESTA study, 307 patients
from four CEE countries (Czech Republic, n¼ 51; Hungary, n¼ 107;
Poland, n¼ 41; Serbia, n¼ 108) were included in this post hoc ana-
lysis. Baseline demographic and disease characteristics were bal-
anced between the two treatment groups (Table 1).
Efficacy assessments
Skin
A significantly greater proportion of participants in the BIW/QW
group (54%) achieved a status of “clear” or “almost clear” for PGA
of psoriasis at week 12 compared with those in the QW/QW group
(40%) (p¼ .02) (Figure 1). By week 24, the proportions had
increased to 68% versus 60%, respectively (p¼ .134). Mean per-
centage improvement from baseline in the PGA of psoriasis at
week 12 was significantly greater in the BIW/QW group than in
the QW/QW group (57% vs. 50%, p¼ .014). At week 24, the mean
percentage improvement from baseline in PGA of psoriasis was
similar for both groups (64% vs. 62%, p¼ .413) (Table 2).
At week 6, the mean improvement from baseline in PASI was
significantly greater in the BIW/QW group than in the QW/QW
group (59% vs. 49%, p¼ .005); this difference between the two
groups was maintained throughout the study up to week 24 (87%
vs. 81%, p< .05) (Figure 2). At weeks 12 and 24, significantly
greater proportions of participants in the ETN 50mg BIW/QW
group than in the ETN 50mg QW/QW group achieved at least
90% improvement in PASI; the BIW/QW regimen was also signifi-
cantly more effective in helping patients attain a 75%
Table 1. Baseline demographics and disease characteristics.
Parameters
ETN 50mg
BIW/QW (n¼ 153)
ETN 50mg
QW/QW (n¼ 154)
Age, years 46.8 (11.5) 46.6 (11.1)
Female gender, n (%) 60 (39.2) 67 (43.5)
BMI, kg/m2 27.6 (4.7) 28.1 (5.6)
Duration of PsA, years 7.0 (6.8) 7.0 (6.4)
Duration of psoriasis, years 19.7 (11.8) 18.7 (12.6)
PGA of psoriasis 3.6 (0.7) 3.7 (0.6)
BSA affected by psoriasis, % 31.6 (23.1) 29.9 (22.9)
PASI 20.0 (11.2) 19.0 (9.5)
Swollen joint count 15.7 (18.4) 18.0 (18.6)
Tender joint count 23.3 (21.1) 24.5 (20.3)
Previous topical steroids, n (%) 97 (63.4) 81 (52.6)
CRP, mg/L 14.5 (24.2) 18.3 (33.6)
All values shown are means (SD) unless otherwise stated. BIW: twice weekly;
BSA: body surface area; CRP: C-reactive protein; ETN: etanercept; PASI: psoriasis
area and severity index; PGA: physician global assessment; PsA: psoriatic arth-
ritis; QW: once weekly.
Figure 1. PGA psoriasis: participants achieving “clear” or “almost clear” responses
at 12weeks (p¼ .02) and 24weeks. LOCF data. BIW: twice weekly; ETN: etaner-
cept; LOCF: last observation carried forward; PGA: physician’s global assessment;
QW: once weekly.
Table 2. Skin manifestations.
Parameter
ETN 50mg
BIW/QW (n¼ 153)
ETN 50mg
QW/QW (n¼ 154) p value
PGA psoriasis, Mean score (% change from baseline)
Baseline 3.63 3.69 .364
Week 12 1.57 (56.7) 1.85 (49.9) .014
Week 24 1.30 (64.2) 1.43 (61.5) .413
PASI, Mean score (% change from baseline)
Baseline 19.99 19.01 .413
Week 12 4.34 (78.2) 6.11 (67.9) <.001
Week 24 2.85 (85.7) 3.74 (80.3) .036
Patients achieving PASI response
PASI 50
Week 12 132/151 (87.4) 125/153 (81.7) .169
Week 24 141/151 (93.4) 138/153 (90.2) .314
PASI 75
Week 12 98/151 (64.9) 70/153 (45.8) <.001
Week 24 122/151 (80.8) 110/153 (71.9) .068
PASI 90
Week 12 48/151 (31.8) 31/153 (20.3) .022
Week 24 90/151 (59.6) 67/153 (43.8) .006
LOCF data. BIW: twice weekly; ETN: etanercept; PASI: psoriasis area and severity
index; PGA: physician global assessment; QW: once weekly.
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improvement in PASI at week 12. There was no significant differ-
ence between the regimens in terms of PASI 50 response. The
within-group changes from baseline in PGA of psoriasis and PASI
were statistically significant at all study visits in both ETN groups
(p< .001 for each).
Joint and tendon rheumatic manifestations
ACR 20 response at week 12 was significantly greater in the BIW/
QW group (71.7%) than in the QW/QW group (59.9%) (p¼ .03),
but similar between groups at week 24 (77.6% vs. 75.7%)
(Table 3). The proportions of participants who achieved ACR50
and ACR70 responses were similar in the two groups at weeks 12
and 24 (Table 3).
The proportion of participants who achieved PsARC was similar
in the two groups at week 12 and remained stable at week 24
(Table 3). The mean percentage improvement from baseline in
PGA of arthritis was similar in both groups at weeks 12 and 24.
There was no significant differences between the two ETN groups
regarding the improvement from baseline in the swollen and
painful joint counts, the percentage of subjects with enthesitis
and the number of fingers/toes with dactylitis from the baseline
and weeks 12 and 24 (Table 3). The within-group changes from
baseline in PGA of arthritis and swollen and painful joint scores
were statistically significant at weeks 12 and 24 in both ETN
groups (p< .001 for all).
CRP
Decreases from baseline in mean CRP levels were similar between
the two treatment regimens and significant within each group.
Concentrations decreased from 14.5 (SD 24.2) mg/L at baseline to
5.0 (4.7) mg/L by week 24 in the 50mg BIW/QW group (p< .001)
and from 18.3 (33.6) mg/L to 5.4 (4.5) mg/L (p< .001) in the QW/
QW group.
Safety assessments
ETN was well tolerated in both treatment groups over 24weeks.
Lower AE rates were observed in both treatment groups com-
pared to the overall PRESTA population; AEs were experienced in
a higher proportion of patients in the BIW/QW group (36.6%) than
the QW/QW group (24.7%) (p¼ .026); corresponding values in the
total cohort were 56.2% in the BIW/QW group and 50.9% in the
QW/QW group. The most commonly reported treatment-emergent
adverse events (5% in either treatment group) were upper
respiratory tract infection, injection site reaction and pharyngitis;
none of these was significantly different between treatment groups.
A total of 13 (8%) patients in the BIW/QW group and five (3%) in
the QW/QW group reported serious adverse events, including ser-
ious infections. Two (0.7%) serious infections were reported, both
(1.3%) in the QW/QW group. One malignancy, a breast carcinoma
in the BIW/QW group, was reported. No cases of tuberculosis, other
opportunistic infections, or demyelinating disorders were reported
and no participant died during the study.
Discussion
The effectiveness of ETN in the treatment of PsA, including the
inhibition of radiographic disease progression, has been previously
reported in a number of randomized clinical trials and observa-
tional studies. In this subset analysis of the PRESTA trial, we eval-
uated the efficacy and safety of two different ETN (4,8,9) regimens
in subjects from CEE with both moderate-to-severe psoriasis and
active PsA. Overall, baseline demographics and disease characteris-
tics were similar in the CEE population and the total PRESTA
cohort, although the swollen and tender joint counts appeared to
be higher in CEE subjects. While both ETN 50mg BIW/QW and
50mg QW/QW regimens significantly improved skin manifesta-
tions of psoriasis, the twice-weekly regimen had a significantly
greater effect on the physician global assessment of psoriasis (at
week 12) and PASI75 and PASI90 responses than the once-weekly
treatment. Improvement from baseline in PASI was significantly
greater in the BIW/QW group than in the QW/QW group after six
weeks of treatment and this difference between regimens was
maintained up to week 24. These findings are similar to those
Figure 2. PASI: mean percentage improvement from baseline. LOCF data.p< .01; †p< .05. BIW: twice weekly; ETN: etanercept; LOCF: last observation car-
ried forward; PASI: psoriasis area and severity index; PGA: physician’s global
assessment; QW: once weekly.
Table 3. Joint and tendon rheumatic manifestations.
Parameter
ETN 50mg
BIW/QW (n¼ 153)
ETN 50mg
QW/QW (n¼ 154) p value
Patients achieving ACR response, n (%)
ACR 20
Week 12 109/152 (71.7) 91/152 (59.9) .030
Week 24 118/152 (77.6) 115/152 (75.7) .685
ACR 50
Week 12 71/152 (46.7) 56/152 (36.8) .082
Week 24 90/152 (59.2) 91/152 (59.9) .907
ACR 70
Week 12 33/152 (21.7) 29/152 (19.1) .570
Week 24 60/152 (39.5) 58/152 (38.2) .814
Patients achieving PsARC, n (%)
Week 12 126/153 (82.4) 117/154 (76.0) .170
Week 24 131/153 (85.6) 128/154 (83.1) .546
PGA arthritis, Mean score (% change from baseline)
Baseline 53.82 55.80 .396
Week 12 19.55 (63.6) 21.65 (61.2) .489
Week 24 13.69 (74.6) 14.23 (74.6) .962
Painful joints, Mean score (% change from baseline)
Baseline 23.25 24.50 .600
Week 12 9.63 (58.8) 11.50 (53.3) .350
Week 24 6.59 (71.8) 7.10 (71.2) .946
Swollen joints, Mean score (% change from baseline)
Baseline 15.69 18.01 .275
Week 12 5.81 (63.2) 7.50 (58.6) .607
Week 24 3.98 (74.8) 3.82 (78.9) .412
Patients reporting enthesitis, n (%)
Baseline 74/153 (48.4) 69/154 (44.8) .532
Week 12 25/151 (16.6) 32/150 (21.3) .291
Week 24 16/146 (11.0) 15/148 (10.1) .818
Patients with dactylitis >0 (total number of fingers and toes)
N¼ 61 N¼ 74
Baseline 4.7 (5.6) 4.7 (5.6) –
Week 12 1.8 (4.2) 2.1 (4.8) –
Week 24 1.5 (4.5) 1.5 (4.7) –
LOCF data. ACR: American College of Rheumatology; BIW: twice weekly; ETN:
etanercept; PGA: physician global assessment; PsARC: Psoriatic Arthritis Response
Criteria; QW: once weekly.
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reported for the overall PRESTA study although a significant differ-
ence between the two regimens was observed up to week 12 in
the total population.
Both ETN regimens achieved improvements from baseline in
various joint components. However, apart from ACR 20 response
at week 12, there were no significant differences between treat-
ment groups in effects on joint manifestations: ACR50 and ACR70
responses were similar in the BIW/QW and QW/QW groups, as
were swollen and painful joint scores and levels of enthesitis and
dactylitis. Improvement observed in PsARC was also similar with
both regimens.
These findings are similar to those of the overall PRESTA study.
In 754 patients randomized at 98 sites worldwide, ETN 50mg
administered twice weekly provided greater improvement in skin
outcomes than once-weekly administration but similar effects on
joint outcomes. Further analyses have shown that the beneficial
effects of ETN on skin and joint manifestations have enhanced the
quality of life of patients with PsA. Both ETN 50mg BIW/QW and
50mg QW/QW have been shown to provide sustained improve-
ments in skin-related, patient-reported health outcomes within
three weeks of commencing therapy (10). ETN treatment also
resulted in reductions in the time taken off sick and job responsi-
bility changes due to disease (11).
Overall, both ETN regimens were safe and well tolerated.
Reported adverse event rates in patients from CEE were lower
than those reported in the total PRESTA population (6). The
explanation for this difference is not readily apparent. Unlike in
the overall study, the proportion of patients experiencing adverse
events was significantly higher in the BIW/QW group than the
QW/QW group.
Evidence suggests that RA patients are generally in poorer
health in CEE countries than in Western European countries, and
one possible cause is the slower and more restricted utility of bio-
logical treatments. Data indicate that uptake of biologics for the
treatment of RA is markedly lower in CEE countries (1–5% of
patients) than in Western Europe (11–12%) (12), and it is reason-
able to suppose that a similar if not greater disparity exists for the
management of PsA. Concerns have also been raised about the
substantial variability across CEE countries in access to biologic
therapy for the treatment of inflammatory bowel disease (13). The
limited use of biologics in CEE has been attributed not only to
varying economic conditions across geographical locations
but also to other determining factors, such as restrictive national
clinical guidelines, administrative obstacles and availability of
care (12).
Overall, there continues to be a shortage of data on the utility
of TNFa inhibitors for the management of inflammatory rheumatic
diseases in CEE populations. While some progress has been made
in certain countries, the paucity of published data is still concern-
ing. With the lack of clinical analyses and health economic evalua-
tions the management of PsA remains a major issue (14). In view
of the large gaps in basic information, there is an urgent need to
perform more studies focusing specifically on CEE populations or
post hoc analyses of larger multinational trials such as reported
here.
In conclusion, the study in PsA patients from CEE demon-
strated that both ETN dose regimens provided significant
improvements in treatment efficacy without new safety signals.
Clinical improvement in skin manifestations occurred earlier and
was greater in those patients receiving ETN 50mg BIW/QW com-
pared with patients receiving 50mg QW/QW. Both treatments
were well tolerated. These data suggest that ETN is effective
for the treatment of PsA in populations from regions where
prior data are limited and will improve the quality of treatment of
these patients. We hope that our findings help to address the
dearth of information on the efficacy and safety of TNFa inhibitors
in the management of PsA in CEE and ensure that treatment rec-
ommendations for the use of biologic drugs in PsA in CEE are
allowed to be based on evidence-based decision making, rather
than limited by financial constraints.
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